177 related articles for article (PubMed ID: 38304254)
1. Pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage IIIB small cell lung cancer: a case report and literature review.
Mei T; Wang T; Lei C; Jiang D; Zhou Q
Front Immunol; 2023; 14():1272450. PubMed ID: 38304254
[TBL] [Abstract][Full Text] [Related]
2. Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review.
Zhou N; Chen Y; Huang Q; Jiang L; Liao H; Gou H; Lu Y; Che G; Zhang Y
Front Immunol; 2023; 14():1111325. PubMed ID: 36911701
[TBL] [Abstract][Full Text] [Related]
3. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
4. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
Cheng Y; Han L; Wu L; Chen J; Sun H; Wen G; Ji Y; Dvorkin M; Shi J; Pan Z; Shi J; Wang X; Bai Y; Melkadze T; Pan Y; Min X; Viguro M; Li X; Zhao Y; Yang J; Makharadze T; Arkania E; Kang W; Wang Q; Zhu J;
JAMA; 2022 Sep; 328(12):1223-1232. PubMed ID: 36166026
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report.
Yang RX; Hei Y; Zhu WT; Wang QR; Zhang HM; Chen Y
Curr Oncol; 2022 Aug; 29(9):6203-6210. PubMed ID: 36135056
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
Zhang T; Li W; Diwu D; Chen L; Chen X; Wang H
Front Immunol; 2023; 14():1197044. PubMed ID: 37435087
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review.
Yin C; Hu B; Yang X; Kou L; Tian B; Wang C; Li S; Liu B; Ge J
World J Surg Oncol; 2023 Sep; 21(1):304. PubMed ID: 37749594
[TBL] [Abstract][Full Text] [Related]
8. Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: a Prospective, Single-arm and Multicentre Study.
Huang J; Zhang XH; Cai Y; Yang D; Shi J; Xing P; Xu T; Wu L; Su W; Xu R; Wei T; Chen HJ; Yang JJ
Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):39-45. PubMed ID: 37977903
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China.
Xiang G; Jiang T; Gan L; Wu Y; Zhang N; Xing H; Su H; Li Y; Peng D; Ni R; Liu Y
Front Immunol; 2023; 14():1223020. PubMed ID: 37720211
[TBL] [Abstract][Full Text] [Related]
10. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer.
Rusch VW; Nicholas A; Patterson GA; Waqar SN; Toloza EM; Haura EB; Raz DJ; Reckamp KL; Merritt RE; Owen DH; Finley DJ; McNamee CJ; Blasberg JD; Garon EB; Mitchell JD; Doebele RC; Baciewicz F; Nagasaka M; Pass HI; Schulze K; Johnson A; Bunn PA; Johnson BE; Kris MG; Kwiatkowski DJ; Wistuba II; Chaft JE; Carbone DP; Lee JM
J Thorac Cardiovasc Surg; 2023 Mar; 165(3):828-839.e5. PubMed ID: 36369159
[TBL] [Abstract][Full Text] [Related]
11. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
12. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004).
Zhou C; Hu Y; Arkania E; Kilickap S; Ying K; Xu F; Wu L; Wang X; Viguro M; Makharadze T; Sun H; Luo F; Shi J; Zang A; Pan Y; Chen Z; Jia Z; Kuchava V; Lu P; Zhang L; Cheng Y; Kang W; Wang Q; Yu H; Li J; Zhu J;
Cancer Cell; 2024 Feb; 42(2):198-208.e3. PubMed ID: 38181795
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis.
Wang S; Li Y; Liu Z; Tian W; Zeng Y; Liu J; Zhang S; Peng Y; Wu F
Lung Cancer; 2023 Apr; 178():47-56. PubMed ID: 36774774
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma.
Xu H; Wang W; Yin J; Song C; Li L; Sun Z
Drug Des Devel Ther; 2022; 16():4269-4277. PubMed ID: 36540715
[TBL] [Abstract][Full Text] [Related]
15. Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy.
Li L; Chen T; Lai H; Zhang A; Zhao X; Wu J; Hong H; Wu L; Lin S; Wang K; Zhang H; Fang C
Medicine (Baltimore); 2022 Jun; 101(23):e29336. PubMed ID: 35687776
[TBL] [Abstract][Full Text] [Related]
16. Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.
Heymach JV; Mitsudomi T; Harpole D; Aperghis M; Jones S; Mann H; Fouad TM; Reck M
Clin Lung Cancer; 2022 May; 23(3):e247-e251. PubMed ID: 34819266
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection in patients with stage I-IIIA small-cell lung cancer: a retrospective single-arm clinical trial.
Liu J; Wang L; Shu W; Zhang L; Wang Y; Lv W; Zhu L; Hu J
J Thorac Dis; 2022 Nov; 14(11):4405-4415. PubMed ID: 36524062
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Public Health; 2023; 11():1156427. PubMed ID: 37727602
[TBL] [Abstract][Full Text] [Related]
19. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
[TBL] [Abstract][Full Text] [Related]
20. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Rothschild SI; Zippelius A; Eboulet EI; Savic Prince S; Betticher D; Bettini A; Früh M; Joerger M; Lardinois D; Gelpke H; Mauti LA; Britschgi C; Weder W; Peters S; Mark M; Cathomas R; Ochsenbein AF; Janthur WD; Waibel C; Mach N; Froesch P; Buess M; Bohanes P; Godar G; Rusterholz C; Gonzalez M; Pless M;
J Clin Oncol; 2021 Sep; 39(26):2872-2880. PubMed ID: 34251873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
